Evotec

Evotec

Biotechnology Research

#researchneverstops

About us

Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.

Website
http://www.evotec.com
Industry
Biotechnology Research
Company size
5,001-10,000 employees
Headquarters
Hamburg
Type
Public Company
Specialties
CNS, Oncology, Pain, Neurosciences, Inflammation, Metabolic disease, Infection, Respiratory diseases, Drug-Discovery, CMC, IND enabling, and Drug Development

Locations

  • Primary

    Manfred Eigen Campus

    Essener Bogen 7

    Hamburg, 22419, DE

    Get directions

Employees at Evotec

Updates

Affiliated pages

Similar pages

Browse jobs

Funding

Evotec 14 total rounds

Last Round

Grant

US$ 2.5M

See more info on crunchbase